An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Tivicay

Chemical Namedolutegravir
Dosage FormTablet (oral; 50mg)
Drug ClassInhibitors
SystemBlood
CompanyViiV Healthcare
Approval Year2013

Indication

  • For the treatment of HIV-1 infection in adults and children aged 12 years and older and weighing at least 40 kg.
Last updated on 4/29/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Tivicay (dolutegravir) Prescribing Information 2013ViiV Healthcare, Research Triangle Park, NC
Document TitleYearSource
Effectiveness and safety of dolutegravir two-drug regimensin virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.2021HIV Medicine
Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400mg among antiretroviral therapies for first-line HIV treatment: A systematic literature review and network meta-analysis.2020EClinicalMedicine
Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysis.2019PLoS One
Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.2019BMC infectious Diseases
Safety and pharmacokinetics of dolutegravir in HIV-positive pregnant women: a systematic review.2018Journal of Virus Eradication
Dolutegravir (DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.2016AIDS Research and Therapy
Dolutegravir plus two nucleoside reverse transcriptase inhibitors versus efavirenz plus two nucleoside reverse transcriptase inhibitors as Initial antiretroviral therapy for people with HIV: A systematic review.2016PLoS One
Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. 2016The Lancet HIV
Therapy-emergent drug resistance to integrase strand transfer inhibitors in HIV-1 patients: A subgroup meta-analysis of clinical trials.2016PLoS One
Document TitleYearSource
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.2021National Institute of Health
European AIDS clinical society guidelines v10.1 October 2020.2020European AIDS Clinical Society